Reviva Pharmaceuticals Holdings, Inc. (RVPH)
Nasdaq · Healthcare · Biotechnology
$0.36−10.22%as of Nov 5, 2026, 4:50 AM ET
- Market cap
- $4.7M
- 52-week range
- $0.262 – $15.40
- 52-week change
- −96.54%
- EPS (trailing)
- −$1.44
- Next earnings
- Nov 12, 2026
Fiscal year to Dec 2025
- Net income
- −$19.9M
From the company’s annual report on SEC EDGAR.
About Reviva Pharmaceuticals Holdings, Inc.
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, such as schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis. It also engages in the clinical development for respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis. In addition, the company is in preclinical development for the treatment of psoriasis; and RP1208 for the treatment of depression and obesity. The company was founded in 2018 and is headquartered in Cupertino, California.
Headquarters: Cupertino, United States · 14 employees · revivapharma.com